In last trading session, Nurix Therapeutics Inc (NASDAQ:NRIX) saw 1.23 million shares changing hands with its beta currently measuring 2.24. Company’s recent per share price level of $11.38 trading at $0.91 or 8.69% at ring of the bell on the day assigns it a market valuation of $863.60M. That closing price of NRIX’s stock is at a discount of -159.75% from its 52-week high price of $29.56 and is indicating a premium of 8.88% from its 52-week low price of $10.37. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.26 million shares which gives us an average trading volume of 812.76K if we extend that period to 3-months.
For Nurix Therapeutics Inc (NRIX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.33. Splitting up the data highlights that, out of 16 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 13 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Nurix Therapeutics Inc (NASDAQ:NRIX) trade information
Upright in the green during last session for gaining 8.69%, in the last five days NRIX remained trading in the red while hitting it’s week-highest on Thursday, 03/27/25 when the stock touched $11.38 price level, adding 13.13% to its value on the day. Nurix Therapeutics Inc’s shares saw a change of -39.60% in year-to-date performance and have moved -10.60% in past 5-day. Nurix Therapeutics Inc (NASDAQ:NRIX) showed a performance of -20.20% in past 30-days. Number of shares sold short was 12.17 million shares which calculate 14.75 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 34 to the stock, which implies a rise of 66.53% to its current value. Analysts have been projecting 16 as a low price target for the stock while placing it at a high target of 41. It follows that stock’s current price would drop -40.6% in reaching the projected high whereas dropping to the targeted low would mean a loss of -40.6% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -38.86% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -11.79% while estimates for its earnings growth in next 5 years are of -5.21%.
Nurix Therapeutics Inc (NASDAQ:NRIX)’s Major holders
Insiders are in possession of 1.35% of company’s total shares while institution are holding 109.89 percent of that, with stock having share float percentage of 111.39%. Investors also watch the number of corporate investors in a company very closely, which is 109.89% institutions for Nurix Therapeutics Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at NRIX for having 6.82 million shares of worth $142.33 million. And as of 2024-06-30, it was holding 10.9334 of the company’s outstanding shares.
The second largest institutional holder is REDMILE GROUP, LLC, which was holding about 4.42 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.0917 of outstanding shares, having a total worth of $92.32 million.
